Peripartum cardiomyopathy (PPCM) is a rare, severe and potentially life-threatening disorder of largely unknown etiology and pathophysiology, with unexplained geographical differences and heterogeneous presentation. Investigators hypothesize that a network-based multidisciplinary strategy integrating clinical and molecular phenotyping of PPCM patients might anticipate diagnosis, optimize treatments, and identify novel mechanisms to achieve the unmet goal of personalized medicine.
Specific aims of this study are: a) to create a multicenter pilot registry of PPCM in different areas in Italy to assess incidence and prevalence of this rare disease, associated comorbidities and risk factors. b) to deeply characterize identified PPCM patients through clinical, imaging, genetic, biochemical, and molecular phenotyping. c) to gain novel mechanistic information on PPCM by performing deep clinical and molecular phenotyping in available biobanks samples of patients with PPCM and healthy controls.
Study Type
OBSERVATIONAL
Enrollment
40
Molecular and genetic screening
Federico II University Hospital
Naples, Italy
RECRUITINGDeath or hospitalization due to heart failure
Death or hospitalization due to heart failure during the follow-up period
Time frame: 0-6 months
Development of significant cardiac arrhythmias
New onset sustained supraventricular or ventricular arrhythmias or conduction blocks during the follow-up period
Time frame: 0-6 months
Left ventricular dysfunction
Left ventricular % ejection fraction during the follow-up period
Time frame: 0-6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.